AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

In a recently published study, researchers based at Université Paris-Saclay identified OXA-1186, a novel carbapenemase related to the previously known OXA-198 enzyme, in a clinical isolate of ...